OverviewChartTechnicalNewsTraderScreen

XBiotech Inc/  CA98400H1029  /

NASDAQ
2024-07-25  10:00:00 PM Chg. +0.7100 Volume Bid10:40:52 PM Ask10:40:52 PM High Low
7.0200USD +11.25% 97,264
Turnover: 462,465.2037		 6.5000Bid Size: 100 7.1000Ask Size: 400 7.0900 6.2900
GlobeNewswire 06-18 XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treat...
GlobeNewswire 01-04 XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GlobeNewswire 01-04 XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
GlobeNewswire 2023-11-14 Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
GlobeNewswire 2023-09-26 XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate T...
GlobeNewswire 2023-08-30 XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natr...
GlobeNewswire 2022-01-26 XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natr...
GlobeNewswire 2021-12-13 FDA Approves XBiotech’s IND in Rheumatology
GlobeNewswire 2021-12-11 Annual Changes to the Nasdaq Biotechnology Index
GlobeNewswire 2021-10-28 XBiotech to Launch Novel Candidate Therapy for Stroke
GlobeNewswire 2021-09-08 Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in ...
GlobeNewswire 2021-08-30 XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
GlobeNewswire 2021-07-30 XBiotech Announces Payment of Dividend to Holders of Common Stock
GlobeNewswire 2021-07-06 XBiotech Announces Dividend to Holders of Common Stock
GlobeNewswire 2021-06-30 XBiotech Announces Receipt of $75 Million from Sale of Antibody
GlobeNewswire 2021-06-23 XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of P...
GlobeNewswire 2021-05-03 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptiv...
GlobeNewswire 2021-04-19 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled S...
GlobeNewswire 2021-01-21 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
GlobeNewswire 2021-01-19 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
GlobeNewswire 2020-11-19 XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influen...
GlobeNewswire 2020-09-21 XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co...
GlobeNewswire 2020-08-24 XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emerg...
TeleTrader 2020-08-17 Wall Street ends mixed as Nasdaq reaches record high
TeleTrader 2020-08-17 Europe closes higher on virus treatment hopes